AR094921A1 - Derivados de 2-acilaminotiazol o su sal - Google Patents
Derivados de 2-acilaminotiazol o su salInfo
- Publication number
- AR094921A1 AR094921A1 ARP140100632A ARP140100632A AR094921A1 AR 094921 A1 AR094921 A1 AR 094921A1 AR P140100632 A ARP140100632 A AR P140100632A AR P140100632 A ARP140100632 A AR P140100632A AR 094921 A1 AR094921 A1 AR 094921A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- alkyl
- salt
- compound
- acilaminotiazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se proporciona un compuesto que es de utilidad como un ingrediente activo de una composición farmacéutica para el tratamiento de disfunciones de almacenamiento, disfunciones de evacuación y enfermedades del tracto urinario inferior. Reivindicación 1: Un compuesto de la fórmula (1) o una de sus sales, donde R¹ es -N(-R¹¹)(-R¹²) o amino cíclico que puede estar sustituido; R¹¹ es alquilo C₁₋₆; R¹² es alquilo C₁₋₆ que puede estar sustituido o cicloalquilo C₃₋₈ que puede estar sustituido; R² es arilo que puede estar sustituido, un heteroanillo aromático monocíclico que puede estar sustituido o un heteroanillo aromático bicíclico que puede estar sustituido; y R³ es -H, -OH, -O-(alquilo C₁₋₆) o halógeno.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013039964 | 2013-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR094921A1 true AR094921A1 (es) | 2015-09-09 |
Family
ID=51428316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100632A AR094921A1 (es) | 2013-02-28 | 2014-02-27 | Derivados de 2-acilaminotiazol o su sal |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9562044B2 (es) |
| EP (1) | EP2963036B1 (es) |
| JP (1) | JP6183451B2 (es) |
| KR (1) | KR102164821B1 (es) |
| CN (1) | CN105008353B (es) |
| AR (1) | AR094921A1 (es) |
| AU (1) | AU2014221726B2 (es) |
| BR (1) | BR112015020963B1 (es) |
| CA (1) | CA2902302C (es) |
| EA (1) | EA027179B1 (es) |
| ES (1) | ES2748402T3 (es) |
| HK (1) | HK1214255A1 (es) |
| IL (1) | IL240764A0 (es) |
| MX (1) | MX368539B (es) |
| MY (1) | MY190361A (es) |
| PH (1) | PH12015501899B1 (es) |
| PL (1) | PL2963036T3 (es) |
| PT (1) | PT2963036T (es) |
| SA (1) | SA515360956B1 (es) |
| SG (1) | SG11201506713TA (es) |
| TW (1) | TWI647227B (es) |
| UA (1) | UA118445C2 (es) |
| WO (1) | WO2014133056A1 (es) |
| ZA (1) | ZA201506296B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3150581T3 (pl) * | 2014-05-28 | 2020-07-13 | Astellas Pharma Inc. | Pochodne pirydyny |
| SG10202000463YA (en) | 2014-06-06 | 2020-02-27 | Astellas Pharma Inc | 2-acylaminothiazole derivative or salt thereof |
| RU2702106C2 (ru) * | 2014-08-26 | 2019-10-04 | Астеллас Фарма Инк. | Производное 2-аминотиазола или его соль |
| EP3228616B1 (en) | 2014-12-05 | 2019-10-16 | Astellas Pharma Inc. | Pyridine derivatives |
| AR102849A1 (es) * | 2015-03-09 | 2017-03-29 | Astellas Pharma Inc | Compuesto de piridina bicíclica |
| TW201713343A (zh) * | 2015-04-28 | 2017-04-16 | 安斯泰來製藥股份有限公司 | 經口投與用醫藥組成物 |
| ES2828426T3 (es) * | 2015-05-20 | 2021-05-26 | Kent Imaging | Compensación automática de la atenuación de luz debida a melanina epidérmica en imágenes de la piel |
| RU2709496C1 (ru) * | 2019-08-01 | 2019-12-18 | Марат Феликсович Фазылов | Способ получения аватромбопага |
| CN115916776A (zh) * | 2020-06-09 | 2023-04-04 | 艾尼莫生物科技公司 | 胶原蛋白1翻译抑制剂及其使用方法 |
| EP3967311A1 (en) | 2020-09-11 | 2022-03-16 | Astellas Pharma Inc. | Compounds for use in the treatment of dry mouth |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7638536B2 (en) | 2002-01-18 | 2009-12-29 | Astellas Pharma Inc. | 2-Acylaminothiazole derivative or salt thereof |
| AR044134A1 (es) * | 2003-05-02 | 2005-08-24 | Novartis Ag | Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas. |
| CN100445281C (zh) * | 2003-05-02 | 2008-12-24 | 诺瓦提斯公司 | 与毒蕈碱性m3受体结合的奎宁环衍生物 |
| CA2529686C (en) | 2003-07-17 | 2010-06-15 | Astellas Pharma Inc. | 2-acylaminothiazole derivative or salt thereof |
| JP4665769B2 (ja) | 2005-01-12 | 2011-04-06 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体の製造法 |
| JP4774995B2 (ja) | 2005-01-12 | 2011-09-21 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体を有効成分とする医薬組成物 |
| JP5889895B2 (ja) | 2010-07-29 | 2016-03-22 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ａｍｐｋ活性化複素環化合物およびその使用方法 |
-
2014
- 2014-02-26 TW TW103106494A patent/TWI647227B/zh not_active IP Right Cessation
- 2014-02-27 WO PCT/JP2014/054803 patent/WO2014133056A1/ja active Application Filing
- 2014-02-27 PT PT147573778T patent/PT2963036T/pt unknown
- 2014-02-27 EP EP14757377.8A patent/EP2963036B1/en active Active
- 2014-02-27 PL PL14757377T patent/PL2963036T3/pl unknown
- 2014-02-27 ES ES14757377T patent/ES2748402T3/es active Active
- 2014-02-27 MY MYPI2015702844A patent/MY190361A/en unknown
- 2014-02-27 US US14/770,648 patent/US9562044B2/en active Active
- 2014-02-27 KR KR1020157026269A patent/KR102164821B1/ko active IP Right Grant
- 2014-02-27 CN CN201480010396.6A patent/CN105008353B/zh active Active
- 2014-02-27 BR BR112015020963-7A patent/BR112015020963B1/pt not_active IP Right Cessation
- 2014-02-27 UA UAA201508421A patent/UA118445C2/uk unknown
- 2014-02-27 AR ARP140100632A patent/AR094921A1/es unknown
- 2014-02-27 AU AU2014221726A patent/AU2014221726B2/en not_active Ceased
- 2014-02-27 MX MX2015011202A patent/MX368539B/es active IP Right Grant
- 2014-02-27 EA EA201591391A patent/EA027179B1/ru not_active IP Right Cessation
- 2014-02-27 CA CA2902302A patent/CA2902302C/en not_active Expired - Fee Related
- 2014-02-27 JP JP2015503003A patent/JP6183451B2/ja not_active Expired - Fee Related
- 2014-02-27 SG SG11201506713TA patent/SG11201506713TA/en unknown
-
2015
- 2015-08-23 IL IL240764A patent/IL240764A0/en active IP Right Grant
- 2015-08-27 ZA ZA2015/06296A patent/ZA201506296B/en unknown
- 2015-08-27 PH PH12015501899A patent/PH12015501899B1/en unknown
- 2015-08-27 SA SA515360956A patent/SA515360956B1/ar unknown
-
2016
- 2016-02-25 HK HK16102148.9A patent/HK1214255A1/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR094921A1 (es) | Derivados de 2-acilaminotiazol o su sal | |
| CY1121071T1 (el) | Παραγωγα ναφθυριδινης ως ανταγωνιστες ιντεγκρινης αλφα v βητα 6 για τη θεραπεια π.χ. ινωτικων νοσων | |
| AR108768A2 (es) | Compuestos de piridina y pirazol y sus usos para la modulación de hemoglobina | |
| CY1120703T1 (el) | Ετεροκυκλικες ενωσεις και χρησεις αυτων | |
| CY1122712T1 (el) | ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ ΠΥΡΑΖΟΛΟΠΥΡΙΜΙΔΙΝΗΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΣΧΕΤΙΚΩΝ ΜΕ PI3Kδ ΔΙΑΤΑΡΑΧΩΝ | |
| CL2016002011A1 (es) | Derivados de heterociclos bicíclicos condensados sustituidos con 2-(het)arilo como agentes para combatir parásitos | |
| DOP2017000149A (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| AR106141A1 (es) | Métodos e intermediarios para la preparación de derivados de ácidos biliares | |
| CR20160191A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| CL2016001458A1 (es) | Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo. | |
| CR20150078A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| CR20150418A (es) | Compuestos de tetrahidropirrolotiazina | |
| CU24419B1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas | |
| UY33885A (es) | Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| EA201691625A1 (ru) | Ароматические гетероциклические соединения как противовоспалительные соединения | |
| CU20160192A7 (es) | Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble | |
| CO2021005532A2 (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| AR103680A1 (es) | Inhibidores selectivos de bace1 | |
| AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
| EA201691600A1 (ru) | Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений | |
| AR100748A1 (es) | Derivado de 2-acilaminotiazol o su sal | |
| BR112017000730B8 (pt) | Derivados de pirrolidinona como inibidores de metap-2, e medicamentos | |
| GT201400167A (es) | Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2 | |
| UY36124A (es) | Derivados de carboxamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |